133 related articles for article (PubMed ID: 8774638)
1. The relationship between borderline ovarian tumors and epithelial ovarian carcinoma: epidemiologic, pathologic, and molecular aspects.
Link CJ; Kohn E; Reed E
Gynecol Oncol; 1996 Mar; 60(3):347-54. PubMed ID: 8774638
[TBL] [Abstract][Full Text] [Related]
2. [Clinical characteristics of borderline ovarian tumors and stage I epithelial ovarian cancer: an analysis of 143 cases].
Zhao Y; Wang Y; Shen Dh; Song Rn; Xu Q; Li Y; Cui H; Tang J; Wei Lh
Beijing Da Xue Xue Bao Yi Xue Ban; 2011 Feb; 43(1):123-8. PubMed ID: 21321635
[TBL] [Abstract][Full Text] [Related]
3. Ovarian borderline tumors in the 2014 WHO classification: evolving concepts and diagnostic criteria.
Hauptmann S; Friedrich K; Redline R; Avril S
Virchows Arch; 2017 Feb; 470(2):125-142. PubMed ID: 28025670
[TBL] [Abstract][Full Text] [Related]
4. [Serum level and expression of vascular epithelial growth factor in ovarian epithelial carcinoma].
Sun LX; Wu Y; Han HQ; Wang QH
Ai Zheng; 2003 Jan; 22(1):58-61. PubMed ID: 12561438
[TBL] [Abstract][Full Text] [Related]
5. Malignant and borderline epithelial ovarian tumors in the pediatric and adolescent population.
Nasioudis D; Alevizakos M; Holcomb K; Witkin SS
Maturitas; 2017 Feb; 96():45-50. PubMed ID: 28041594
[TBL] [Abstract][Full Text] [Related]
6. Comparison of loss of heterozygosity patterns in invasive low-grade and high-grade epithelial ovarian carcinomas.
Dodson MK; Hartmann LC; Cliby WA; DeLacey KA; Keeney GL; Ritland SR; Su JQ; Podratz KC; Jenkins RB
Cancer Res; 1993 Oct; 53(19):4456-60. PubMed ID: 8402612
[TBL] [Abstract][Full Text] [Related]
7. Genetic alterations of serous borderline tumors of the ovary compared to stage I serous ovarian carcinomas.
Osterberg L; Akeson M; Levan K; Partheen K; Zetterqvist BM; Brännström M; Horvath G
Cancer Genet Cytogenet; 2006 Jun; 167(2):103-8. PubMed ID: 16737908
[TBL] [Abstract][Full Text] [Related]
8. Molecular genetic changes in human epithelial ovarian malignancies.
Gallion HH; Powell DE; Morrow JK; Pieretti M; Case E; Turker MS; DePriest PD; Hunter JE; van Nagell JR
Gynecol Oncol; 1992 Nov; 47(2):137-42. PubMed ID: 1468689
[TBL] [Abstract][Full Text] [Related]
9. Comparing the Copenhagen Index (CPH-I) and Risk of Ovarian Malignancy Algorithm (ROMA): Two equivalent ways to differentiate malignant from benign ovarian tumors before surgery?
Yoshida A; Derchain SF; Pitta DR; Andrade LA; Sarian LO
Gynecol Oncol; 2016 Mar; 140(3):481-5. PubMed ID: 26825617
[TBL] [Abstract][Full Text] [Related]
10. Genetic disparity between morphologically benign cysts contiguous to ovarian carcinomas and solitary cystadenomas.
Zheng J; Benedict WF; Xu HJ; Hu SX; Kim TM; Velicescu M; Wan M; Cofer KF; Dubeau L
J Natl Cancer Inst; 1995 Aug; 87(15):1146-53. PubMed ID: 7674319
[TBL] [Abstract][Full Text] [Related]
11. Identification of allelic losses in benign, borderline, and invasive epithelial ovarian tumors and correlation with clinical outcome.
Saretzki G; Hoffmann U; Röhlke P; Psille R; Gaigal T; Keller G; Höfler H; Löning T; Petersen I; Dietel M
Cancer; 1997 Oct; 80(7):1241-9. PubMed ID: 9317174
[TBL] [Abstract][Full Text] [Related]
12. Overexpression of JARID1B is associated with poor prognosis and chemotherapy resistance in epithelial ovarian cancer.
Wang L; Mao Y; Du G; He C; Han S
Tumour Biol; 2015 Apr; 36(4):2465-72. PubMed ID: 25663457
[TBL] [Abstract][Full Text] [Related]
13. [Borderline tumors of the ovary. New aspects on morphologic prognosis determination].
Dietel M; Bodecker R; Arps H; Bahnsen J; Hölzel F
Geburtshilfe Frauenheilkd; 1985 Apr; 45(4):213-9. PubMed ID: 3891502
[TBL] [Abstract][Full Text] [Related]
14. The development of high-grade serous carcinoma from atypical proliferative (borderline) serous tumors and low-grade micropapillary serous carcinoma: a morphologic and molecular genetic analysis.
Dehari R; Kurman RJ; Logani S; Shih IeM
Am J Surg Pathol; 2007 Jul; 31(7):1007-12. PubMed ID: 17592266
[TBL] [Abstract][Full Text] [Related]
15. Expression and prognostic significance of platelet-derived growth factor and its receptors in epithelial ovarian neoplasms.
Henriksen R; Funa K; Wilander E; Bäckström T; Ridderheim M; Oberg K
Cancer Res; 1993 Oct; 53(19):4550-4. PubMed ID: 8402626
[TBL] [Abstract][Full Text] [Related]
16. Upregulation of centrosomal protein 55 is associated with unfavorable prognosis and tumor invasion in epithelial ovarian carcinoma.
Zhang W; Niu C; He W; Hou T; Sun X; Xu L; Zhang Y
Tumour Biol; 2016 May; 37(5):6239-54. PubMed ID: 26615423
[TBL] [Abstract][Full Text] [Related]
17. Vascular Endothelial Growth Factor (VEGF) Polymorphisms and Serum VEGF Levels in Women With Epithelial Ovarian Cancer, Benign Tumors, and Healthy Ovaries.
González-Palomares B; Coronado Martín PJ; Maestro de Las Casas ML; Veganzones de Castro S; Rafael Fernández S; Vidaurreta Lázaro M; De la Orden García V; Vidart Aragon JA
Int J Gynecol Cancer; 2017 Jul; 27(6):1088-1095. PubMed ID: 28574932
[TBL] [Abstract][Full Text] [Related]
18. DNA hypomethylation-mediated activation of Cancer/Testis Antigen 45 (CT45) genes is associated with disease progression and reduced survival in epithelial ovarian cancer.
Zhang W; Barger CJ; Link PA; Mhawech-Fauceglia P; Miller A; Akers SN; Odunsi K; Karpf AR
Epigenetics; 2015; 10(8):736-48. PubMed ID: 26098711
[TBL] [Abstract][Full Text] [Related]
19. p14 expression differences in ovarian benign, borderline and malignant epithelial tumors.
Cabral VD; Cerski MR; Sa Brito IT; Kliemann LM
J Ovarian Res; 2016 Oct; 9(1):69. PubMed ID: 27770808
[TBL] [Abstract][Full Text] [Related]
20. K-ras mutations in nonmucinous ovarian epithelial tumors: a molecular analysis and clinicopathologic study of 144 patients.
Cuatrecasas M; Erill N; Musulen E; Costa I; Matias-Guiu X; Prat J
Cancer; 1998 Mar; 82(6):1088-95. PubMed ID: 9506354
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
